GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025's Top Research
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — In a move toward longevity, telehealth company Noom now offers microdoses of GLP-1 receptor agonists off-label, including for people with normal body mass index and without diabetes. In a phase III trial…
